Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

Plasmidsaurus, the company that sequences while you sleep, today announced the opening of its tenth global sequencing lab, ...

Provides ReciBioPharm's customers with access to NewBiologix's Xcell-Eng-HEK293 cell lines for advanced therapies <l ...

From connectors and containers to plasmids and platforms, companies work to get these treatments to patients faster and more ...

The move bolsters the CDMO’s commitment to cell and gene therapy by incorporating advanced manufacturing and fill-finish ...

Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) ...

PR Newswire AUSTIN, Texas, May 6, 2025 License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas, May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex ...

Researchers from the University of Birmingham have pinpointed crucial genetic sequences involved in a technique known as ...

The research is on plasmids, small, circular strands of DNA, that allow bacteria to share genes rapidly, and carry genes ...

In this valuable study, the authors demonstrate that TCF7L2 plays a role in the pathogenesis of cachexia in a mouse model of GI cancer. The results are solid, although future studies will need further ...